GlucoTrack Inc. has announced promising results from its first-in-human trial of its implantable continuous blood glucose monitoring (CBGM) system. The findings, which were presented at the American Diabetes Association's 85th Scientific Sessions, highlight the safety and performance of the device, which measures glucose directly from the blood without the need for on-body wearables. This innovative approach, capable of lasting up to three years, aims to redefine diabetes management by offering real-time, accurate readings and minimizing daily disruptions for patients. GlucoTrack's technology is currently limited to investigational use as it progresses toward the next phase of clinical trials.